Profile data is unavailable for this security.
About the company
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
- Revenue in DKK (TTM)34.91m
- Net income in DKK-61.30m
- Incorporated1917
- Employees36.00
- LocationBioporto A/STuborg Havnevej 15, St.HELLERUP 2900DenmarkDNK
- Phone+45 45290000
- Fax+45 45290001
- Websitehttps://bioporto.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gentian Diagnostics ASA | 94.49m | 1.43m | 406.66m | 58.00 | 324.80 | 3.92 | 55.74 | 4.30 | 0.1262 | 0.1262 | 9.35 | 10.47 | 0.7792 | 1.69 | 8.40 | 2,533,190.00 | 1.18 | -10.76 | 1.33 | -11.86 | 51.69 | 41.46 | 1.51 | -26.99 | 5.01 | -- | 0.0394 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Omda AS | 270.82m | -16.73m | 416.79m | 271.00 | -- | 10.24 | 22.78 | 1.54 | -1.27 | -1.27 | 20.92 | 3.03 | 0.5847 | 37.93 | 13.47 | 1,447,038.00 | -3.83 | -4.92 | -7.72 | -6.37 | 93.07 | 90.22 | -6.55 | -9.83 | 1.15 | 0.0681 | 0.8875 | -- | 12.30 | 19.83 | 179.30 | -- | -3.93 | -- |
| Senzime AB (publ) | 35.60m | -84.63m | 418.08m | 52.00 | -- | 2.41 | -- | 11.74 | -1.09 | -1.09 | 0.4595 | 2.38 | 0.1533 | 1.57 | 4.91 | -- | -36.44 | -35.69 | -39.12 | -38.00 | 33.27 | -20.59 | -237.75 | -558.68 | 2.62 | -- | 0.0739 | -- | 154.77 | 61.90 | -1.09 | -- | -3.69 | -- |
| ADDvise Group AB (publ) | 1.05bn | 73.65m | 484.17m | 643.00 | 20.22 | 3.05 | 3.57 | 0.4625 | 0.5935 | 0.5935 | 8.38 | 3.93 | 0.565 | 8.37 | 5.77 | 2,606,250.00 | 3.98 | 3.72 | 4.82 | 4.77 | 42.07 | 48.95 | 7.04 | 5.89 | 1.40 | 2.35 | 0.6969 | 0.9405 | 44.30 | 38.62 | 27.62 | -- | 30.35 | -- |
| OssDsign AB | 82.08m | -58.22m | 499.82m | 25.00 | -- | 3.62 | -- | 6.09 | -1.00 | -1.00 | 1.35 | 2.20 | 0.4033 | 1.32 | 5.96 | 2,656,063.00 | -28.61 | -37.92 | -31.51 | -43.56 | 88.64 | 68.10 | -70.94 | -203.06 | 5.44 | -20.45 | 0.01 | -- | 96.84 | 53.26 | -31.30 | -- | -56.16 | -- |
| Optomed Oyj | 101.44m | -44.68m | 580.53m | 113.00 | -- | 3.15 | -- | 5.72 | -0.3355 | -0.3355 | 0.763 | 1.26 | 0.4267 | 1.75 | 4.06 | 119,307.00 | -18.79 | -12.95 | -22.82 | -15.90 | 64.80 | 65.69 | -44.04 | -27.84 | 2.76 | -20.42 | 0.1313 | -- | 3.00 | 3.47 | 18.84 | -- | 7.26 | -- |
| C Rad AB | 319.97m | 34.40m | 587.82m | 94.00 | 17.53 | 3.10 | 14.59 | 1.84 | 1.58 | 1.58 | 14.72 | 8.96 | 1.23 | 5.04 | 2.72 | 5,712,816.00 | 13.25 | 5.09 | 19.16 | 7.02 | 46.30 | 43.12 | 10.81 | 4.86 | 2.32 | -- | 0.0049 | 0.00 | 40.92 | 17.44 | 375.05 | 10.89 | 33.69 | -- |
| Bactiguard Holding AB | 164.13m | -36.12m | 687.49m | 163.00 | -- | 3.67 | -- | 4.19 | -1.60 | -1.60 | 7.28 | 9.37 | 0.3706 | 3.84 | 7.60 | 1,174,917.00 | -8.16 | -7.56 | -11.32 | -8.81 | 47.53 | 47.91 | -22.01 | -26.28 | 0.5898 | -2.72 | 0.4175 | -- | -11.96 | 6.46 | -161.71 | -- | 8.43 | -- |
| BioPorto A/S | 34.91m | -61.30m | 719.62m | 36.00 | -- | 8.26 | -- | 20.62 | -0.163 | -0.163 | 0.0939 | 0.2014 | 0.3376 | 3.39 | 6.12 | 1,126,000.00 | -59.29 | -71.10 | -74.24 | -96.55 | 70.62 | 63.38 | -175.62 | -239.22 | 4.91 | -52.72 | 0.0507 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
| Paxman AB (publ) | 153.77m | 18.44m | 771.11m | 102.00 | 41.91 | 8.21 | 25.52 | 5.01 | 1.50 | 1.50 | 12.54 | 7.67 | 1.31 | 2.74 | 6.56 | 2,624,791.00 | 15.66 | -5.08 | 20.74 | -7.76 | 70.27 | 69.38 | 11.99 | -5.07 | 1.98 | 12.73 | 0.0838 | -- | 43.99 | 29.35 | 180.69 | -- | 6.26 | -- |
| Sedana Medical AB (publ) | 112.11m | -36.85m | 784.03m | 78.00 | -- | 1.28 | -- | 6.99 | -0.5763 | -0.5763 | 1.75 | 9.56 | 0.1697 | 1.16 | 10.14 | 2,204,317.00 | -5.58 | -5.77 | -5.84 | -6.08 | 70.60 | 64.06 | -32.87 | -36.13 | 6.02 | -30.48 | 0.0076 | -- | 25.23 | 21.59 | 18.90 | -- | 42.12 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 31 Aug 2024 | 650.46k | 0.15% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 114.03k | 0.03% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 73.51k | 0.02% |
| Sydbank A/S (Investment Management)as of 31 Oct 2024 | 60.77k | 0.01% |
